Search results
Results from the WOW.Com Content Network
Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the patent application.
The Swiss competition commission (COMCO) has initiated an investigation against Novartis AG (NYSE: NVS) over the alleged unlawful patent use to reduce competitive pressure. COMCO conducted an ...
Wikipedia entry for Google Patents.Google Patents is a search engine from Google that indexes patents and patent applications from the United States Patent and Trademark Office.
Novartis made use of the EMR to obtain orders against some generic manufacturers who had already launched Gleevec in India. [83] [84] When examination of Novartis' patent application began in 2005, it came under immediate attack from oppositions initiated by generic companies that were already selling Gleevec in India and by advocacy groups ...
For premium support please call: 800-290-4726 more ways to reach us
Novartis fought a seven-year, controversial battle to patent Gleevec in India, and took the case all the way to the Indian Supreme Court, where the patent application was finally rejected. The patent application at the center of the case was filed by Novartis in India in 1998, after India had agreed to enter the World Trade Organization and to ...
To find the answer, we used Google's search algorithm, and the answer is Stanford University. According to Quara user Tom McFarlane, "The invention was made by Larry Page while he was a graduate ...
Bausch + Lomb was in a lawsuit with Novartis which claimed to have patents on a Bausch + Lomb product called PureVision. On June 26, 2002, a federal judge ruled that Bausch & Lomb did infringe on Ciba Vision (a subsidiary of Alcon) patents. [26] On July 2, 2004, the company announced that it had licensed the intellectual property of Novartis. [27]